Show simple item record

dc.contributor.authorBowyer, S
dc.contributor.authorPrithviraj, P
dc.contributor.authorLorigan, P
dc.contributor.authorLarkin, J
dc.contributor.authorMcArthur, G
dc.contributor.authorAtkinson, V
dc.contributor.authorMillward, M
dc.contributor.authorKhou, M
dc.contributor.authorDiem, S
dc.contributor.authorRamanujam, S
dc.contributor.authorKong, B
dc.contributor.authorLiniker, E
dc.contributor.authorGuminski, A
dc.contributor.authorParente, P
dc.contributor.authorAndrews, MC
dc.contributor.authorParakh, S
dc.contributor.authorCebon, J
dc.contributor.authorLong, GV
dc.contributor.authorCarlino, MS
dc.contributor.authorKlein, O
dc.date.accessioned2021-02-04T01:42:20Z
dc.date.available2021-02-04T01:42:20Z
dc.date.issued2016-05-10
dc.identifierpii: bjc2016107
dc.identifier.citationBowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S. & Klein, O. (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. BRITISH JOURNAL OF CANCER, 114 (10), pp.1084-1089. https://doi.org/10.1038/bjc.2016.107.
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/11343/259450
dc.description.abstractBACKGROUND: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. METHODS: We retrospectively identified a cohort of 40 patients with metastatic melanoma who received single-agent anti-PD-1 therapy with pembrolizumab or nivolumab and were treated on progression with ipilimumab at a dose of 3 mg kg(-1) for a maximum of four doses. RESULTS: Ten percent of patients achieved an objective response to ipilimumab, and an additional 8% experienced prolonged (>6 months) stable disease. Thirty-five percent of patients developed grade 3-5 immune-related toxicity associated with ipilimumab therapy. The most common high-grade immune-related toxicity was diarrhoea. Three patients (7%) developed grade 3-5 pneumonitis leading to death in one patient. CONCLUSIONS: Ipilimumab therapy can induce responses in patients who fail the anti-PD-1 therapy with response rates comparable to previous reports. There appears to be an increased frequency of high-grade immune-related adverse events including pneumonitis that warrants close surveillance.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
dc.titleEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
dc.typeJournal Article
dc.identifier.doi10.1038/bjc.2016.107
melbourne.affiliation.departmentMedicine (Austin & Northern Health)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBritish Journal of Cancer
melbourne.source.volume114
melbourne.source.issue10
melbourne.source.pages1084-1089
dc.rights.licenseCC BY-NC-SA
melbourne.elementsid1076647
melbourne.contributor.authorMcArthur, Grant
melbourne.contributor.authorCEBON, JONATHAN
dc.identifier.eissn1532-1827
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record